kras mutation and glutathion glynac Oncogenic Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism: Cell KRAS-Targeted Therapy Doubles as Component
KRAS Targeted Therapy Doubles as Component of Immunotherapy NCI KRAS OriGene Technologies Inc. Targeting KRAS: from metabolic regulation to cancer treatment Molecular Cancer Springer Nature Link Oncometabolites in pancreatic cancer: Strategies and its implications PMC
Pay in 4 interest-free payments of $6.59 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 18 - Sep 23



